George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Surely the size of your holding is relative to the amount you can afford to lose and not the quantity.
ShaunP, in reply to your comment - "The vast majority of the readers of this forum know that I have an important investment holding, probably of far greater importance than your own holding."
- if you would like to enter a willy-measuring competition, perhaps you could tell us the size of your holding :D
https://metro.co.uk/2020/10/20/vaccine-may-never-stop-coronavirus-and-drug-wont-be-ready-in-uk-until-spring-13448418/
Just re-iterating Sir Patrick Vallance comments that a truly sterilising vaccine is unlikely and that the virus will circulate and be endemic forever.
Shaun P
There are 2 issues here I believe, hopes and facts.
Clearly, everybody would like us to free from the virus and wish this terrible tragedy for the world had never happened. So our hopes are that it would be gone. it is a highly emotional issue. Lockdown was a terrible experience for my 2 children especially. However, if I had continued to invest based on these hopes, my pension would have almost halved by now!
The other issue is the facts, and how we address these as investors. I believe that in order to be a good investor, we should not let our emotions cloud our judgement on our decisions (based on Warren Buffet).
I have quoted Max of Novacyt on this, "Covid-19 will eventually be controlled, but testing for it, just as the flu, will forever be handled by labs all over the world. It will be one of over 500 tests Novacyt now has under it’s offering, and those can be used with their rapid Q-series portable devices.
It seems neither vaccines or rapid test rivals can stop Novacyt’s inevitable rise. As their CEO, Graham Mullis said last month – “they’re just getting started”.
Novacyt are the experts on this and it is great to hear their opinion that Covid-19 will eventually be controlled. However, it is also clear that testing will still be required. Novacyt is a great company which will be helping the world to fight the virus for many years to come. it is an ethical investment.
I am also a long term investor in Novacyt, having first invested in March 2020, and now with a significant holding. My SIPP pension is in this and Novacyt has recently been mentioned a safe place for people's pensions. In these difficult times, is is hard to find somewhere that looks safe for one's pension! DYOR, GLA!
Cannot say fairer than that response Shaun P - cheers to that and ongoing balanced analysis!
ShaunP - think you should look at this, now we know the virus is not going to 'go away' next year! Max is The Novacyt Insider's Business & Markets Editor. Here is a quote from the link posted today, regarding the longevity of testing and the control of the virus, so it must be what Novacyt now believe on this matter. It affects the projections in your research, both the forward revenue and achievable P/E ratio of Novacyt. You may want to update these now we have new information, just so as not to deramp our shares!
"As FeverTree fades, investors are rallying behind something fulfilling and fit for a modern investors profile – an ethical business that will go on to take rapid testing to cancer wards, transplant surgeries and virus hotspots from the local business to the depths of the Congo. The market for diagnostics is vast, and while covid-19 testing is now considered by top analysts to last until 2025 to 2027 and be worth over $22 billion – diagnostic testing, excluding covid-19, is significantly larger, worth over $110 billion in the years ahead.
Covid-19 will eventually be controlled, but testing for it, just as the flu, will forever be handled by labs all over the world. It will be one of over 500 tests Novacyt now has under it’s offering, and those can be used with their rapid Q-series portable devices.
It seems neither vaccines or rapid test rivals can stop Novacyt’s inevitable rise. As their CEO, Graham Mullis said last month – “they’re just getting started”.